CTOs on the Move


 
Biorem is a pioneer environmental biotechnology company that designs, manufactures and distributes a comprehensive line of high-efficiency air emissions control systems used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). We offer a selection of products that can be tailored to suit application specific requirements. Biorem ensures optimized long-term performance on every application by custom-designing the solution to meet the individual needs of our clients. With sales and manufacturing offices across the continents, dedicated research facilities, analytical and microbial laboratories, worldwide sales representative network, and a dedicated service division, Biorem has the resources available to ensure that your ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.biorem.biz
  • 7496 Wellington Road 34 RR#3
    Guelph, ON CAN N1H 6H9
  • Phone: 519.767.9100

Executives

Name Title Contact Details

Similar Companies

Aeris Therapeutics Inc

Aeris Therapeutics Inc is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Simcha Therapeutics

Simcha Therapeutics uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system.

ProteomTech Inc

ProteomTech Inc is a Costa Mesa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sensorion

Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT).

Stemline Therapeutics

Stemline Therapeutics is a clinical stage biopharmaceutical company developing oncology compounds that target cancer stem cells.